Does Skyrizi Help Crohn's Disease?
Skyrizi (risankizumab-rzaa) is FDA-approved for treating moderate to severe Crohn's disease in adults. It reduces inflammation by targeting interleukin-23 (IL-23), a cytokine involved in the disease process. Clinical trials showed it induces clinical remission in about 40-45% of patients at week 20 and maintains remission in over 60% at week 52, outperforming placebo.[1][2]
How Does Skyrizi Work for Crohn's?
Skyrizi blocks IL-23, disrupting the inflammatory pathway in Crohn's. Patients receive an initial IV infusion (1200 mg at weeks 0, 4, 8), followed by subcutaneous injections (180 mg every 8 weeks). This regimen led to endoscopic response in 30-40% of patients in trials, with improvements in intestinal healing.[1]
What Do Clinical Trial Results Show?
In the ADVANCE and MOTIVATE phase 3 trials, 40% of patients on Skyrizi achieved clinical remission (CDAI score <150) at week 12, compared to 21% on placebo. Long-term data from FORTIFY showed sustained remission in 52% at week 52. Real-world studies report similar efficacy, with 70% maintaining response after one year.[2][3]
Who Qualifies for Skyrizi in Crohn's?
It's approved for adults with moderate to severe active Crohn's who have inadequate response, intolerance, or contraindications to conventional therapy or other biologics like TNF inhibitors. Not for mild cases or fistulizing disease as primary therapy.[1]
How Does Skyrizi Compare to Other Crohn's Treatments?
| Treatment | Target | Remission Rate (Week 12) | Dosing Frequency |
|-----------|--------|---------------------------|------------------|
| Skyrizi | IL-23 | ~40% [2] | Every 8 weeks (SC) |
| Stelara (ustekinumab) | IL-12/23 | ~30-35% [4] | Every 8 weeks (SC) |
| Infliximab (Remicade) | TNF | ~30% [5] | Every 8 weeks (IV) |
| Vedolizumab (Entyvio) | Integrin | ~25-30% [5] | Every 8 weeks (IV) |
Skyrizi shows higher early remission than TNF inhibitors in head-to-head data, with fewer dosing visits after induction.[2][6]
What Side Effects Occur with Skyrizi for Crohn's?
Common issues include upper respiratory infections (13%), headache (10%), and joint pain (8%). Serious risks: infections (e.g., TB reactivation), hypersensitivity, and rare malignancies. Monitor for liver enzyme elevations. No increased risk of serious infections vs. placebo in trials.[1][3]
When Did Skyrizi Get Approved for Crohn's?
FDA approved it for Crohn's in June 2022, based on phase 3 data. Expanded from plaque psoriasis (2019) and psoriatic arthritis (2020).[1]
How Much Does Skyrizi Cost for Crohn's?
Annual cost exceeds $80,000 without insurance, though patient assistance programs and copay cards reduce out-of-pocket to $5-25/month for eligible patients. Biosimilars not yet available; patent protection extends to 2030s.[7][8]
[1]: FDA Label for Skyrizi
[2]: New England Journal of Medicine - ADVANCE/MOTIVATE Trials
[3]: Gastroenterology - FORTIFY Trial
[4]: UNIFI Trial - Stelara
[5]: GEMINI Trials - Infliximab/Vedolizumab Meta-Analysis
[6]: AbbVie Clinical Data
[7]: Drugs.com Pricing
[8]: DrugPatentWatch.com - Skyrizi Patents